ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. T… Read more
Market Cap & Net Worth: ARS Pharmaceuticals, Inc (SPRY)
ARS Pharmaceuticals, Inc (NASDAQ:SPRY) has a market capitalization of $878.76 Million ($878.76 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7859 globally and #4078 in its home market, demonstrating a -1.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ARS Pharmaceuticals, Inc's stock price $8.89 by its total outstanding shares 98848611 (98.85 Million).
ARS Pharmaceuticals, Inc Market Cap History: 2020 to 2026
ARS Pharmaceuticals, Inc's market capitalization history from 2020 to 2026. Data shows change from $4.58 Billion to $878.76 Million (-17.77% CAGR).
Index Memberships
ARS Pharmaceuticals, Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.04% | #216 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #864 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.06% | #132 of 263 |
Weight: ARS Pharmaceuticals, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ARS Pharmaceuticals, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ARS Pharmaceuticals, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.70x
ARS Pharmaceuticals, Inc's market cap is 11.70 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
130.39x
ARS Pharmaceuticals, Inc's market cap is 130.39 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.58 Billion | $17.84 Million | -$1.06 Million | 256.83x | N/A |
| 2021 | $658.33 Million | $5.51 Million | -$20.24 Million | 119.57x | N/A |
| 2022 | $843.18 Million | $1.32 Million | -$34.68 Million | 640.71x | N/A |
| 2023 | $541.69 Million | $30.00K | -$54.37 Million | 18056.35x | N/A |
| 2024 | $1.04 Billion | $89.15 Million | $8.00 Million | 11.70x | 130.39x |
Competitor Companies of SPRY by Market Capitalization
Companies near ARS Pharmaceuticals, Inc in the global market cap rankings as of March 18, 2026.
Key companies related to ARS Pharmaceuticals, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ARS Pharmaceuticals, Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, ARS Pharmaceuticals, Inc's market cap moved from $4.58 Billion to $ 878.76 Million, with a yearly change of -17.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $878.76 Million | -23.69% |
| 2025 | $1.15 Billion | +10.43% |
| 2024 | $1.04 Billion | +92.52% |
| 2023 | $541.69 Million | -35.76% |
| 2022 | $843.18 Million | +28.08% |
| 2021 | $658.33 Million | -85.63% |
| 2020 | $4.58 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ARS Pharmaceuticals, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $878.76 Million USD |
| MoneyControl | $878.76 Million USD |
| MarketWatch | $878.76 Million USD |
| marketcap.company | $878.76 Million USD |
| Reuters | $878.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.